CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York
Menlo Park, California – February 9, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 2017 BIO CEO & Investor Conference in New York City.
Date: Tuesday, February 14, 2017
Time: 1:00 pm ET
Location: Waldorf Astoria (Room: Park South), New York, NY
A replay of the webcast will also be available on CohBar’s website at: www.cohbar.com following the conference.
About BIO CEO & Investor Conference
Currently in its 19th year, the event is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference features issue-oriented plenary sessions, educational sessions focused on emerging therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
About CohBar’s Clinical Development Program
CohBar’s lead clinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company’s founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed optimized analogs of the MOTS-c peptide, CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities. These drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of Type-2 diabetes.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar’s efforts are focused on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease, type-2 diabetes, cancer, cardiovascular and neurodegenerative disorders. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.
This news release contains forward-looking statements, including statements concerning the company’s plans and prospects, including statements regarding potential development of MBTs into disease therapeutics. These forward-looking statements involve a number of risks and uncertainties including the possibility of unfavorable research results and CohBar’s ability to obtain capital, retain key personnel, expand its research operations, and successfully advance its drug discovery and development programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For additional company information, please visit www.cohbar.com.
Investor and Media Contact:
(650) 446-7888 Ext. 114